Next generation radiotheranostics promoting precision medicine
- Author(s)
- Pomykala, KL; Hadaschik, BA; Sartor, O; Gillessen, S; Sweeney, CJ; Maughan, T; Hofman, MS; Herrmann, K;
- Details
- Publication Year 2023-06,Volume 34,Issue #6,Page 507-519
- Journal Title
- Annals of Oncology
- Publication Type
- Review
- Abstract
- Radiotheranostics is a field of rapid growth with some approved treatments including (131)I for thyroid cancer, (223)Ra for osseous metastases, (177)Lu-DOTATATE for neuroendocrine tumors, and (177)Lu-PSMA (prostate-specific membrane antigen) for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.
- Publisher
- Elsevier
- Keywords
- Male; Humans; Precision Medicine; Artificial Intelligence; Radioisotopes/therapeutic use; *Prostatic Neoplasms/pathology; Radiometry; Prostate-Specific Antigen; *Prostatic Neoplasms, Castration-Resistant/drug therapy; Radiopharmaceuticals/therapeutic use; (177)Lu-DOTATATE; (177)Lu-PSMA; endoradiotherapy; positron emission tomography; radiotheranostics; targeted radioligand therapy
- Department(s)
- Cancer Imaging
- PubMed ID
- 36924989
- Publisher's Version
- https://doi.org/10.1016/j.annonc.2023.03.001
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-07-11 06:23:33
Last Modified: 2023-07-11 06:25:37